SAGE
Income statement / Annual
Last year (2024), Sage Therapeutics, Inc.'s total revenue was $41.24 M,
a decrease of 52.30% from the previous year.
In 2024, Sage Therapeutics, Inc.'s net income was -$400.67 M.
See Sage Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$41.24 M |
$86.46 M |
$7.69 M |
$6.31 M |
$1.11 B |
$6.87 M |
$90.27 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$9.44 M
|
$2.16 M
|
$813,000.00
|
$553,000.00
|
$565,000.00
|
$400,000.00
|
$1.10 M
|
$500,000.00
|
$281,000.00
|
$115,000.00
|
| Gross Profit |
$31.80 M
|
$84.30 M
|
$6.87 M
|
$5.76 M
|
$1.11 B
|
$6.47 M
|
$89.17 M
|
-$500,000.00
|
-$281,000.00
|
-$115,000.00
|
| Gross Profit Ratio |
0.77
|
0.98
|
0.89
|
0.91
|
1
|
0.94
|
0.99
|
0
|
0
|
0
|
| Research and Development Expenses |
$225.90 M
|
$356.24 M
|
$326.16 M
|
$283.17 M
|
$292.71 M
|
$368.82 M
|
$282.11 M
|
$210.28 M
|
$120.76 M
|
$69.36 M
|
| General & Administrative Expenses |
$216.42 M
|
$274.52 M
|
$227.70 M
|
$183.50 M
|
$196.95 M
|
$345.78 M
|
$201.40 M
|
$62.88 M
|
$39.41 M
|
$25.29 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$44.60 M
|
$11.18 M
|
$5.27 M
|
$3.08 M
|
| Selling, General & Administrative Expenses |
$216.42 M
|
$274.52 M
|
$227.70 M
|
$183.50 M
|
$196.95 M
|
$345.78 M
|
$201.40 M
|
$62.88 M
|
$39.41 M
|
$25.29 M
|
| Other Expenses |
$21.85 M
|
$33.39 M
|
$15,000.00
|
$134,000.00
|
$250,000.00
|
$82,000.00
|
$22,000.00
|
-$64,000.00
|
-$35,000.00
|
-$23,000.00
|
| Operating Expenses |
$464.17 M
|
$630.76 M
|
$553.86 M
|
$466.66 M
|
$489.67 M
|
$714.59 M
|
$483.51 M
|
$273.16 M
|
$160.16 M
|
$94.65 M
|
| Cost And Expenses |
$473.61 M
|
$666.69 M
|
$554.68 M
|
$467.22 M
|
$490.23 M
|
$714.99 M
|
$483.51 M
|
$273.16 M
|
$160.16 M
|
$94.65 M
|
| Interest Income |
$31.68 M
|
$38.74 M
|
$14.19 M
|
$2.88 M
|
$9.60 M
|
$27.80 M
|
$20.33 M
|
$3.10 M
|
$1.21 M
|
$178,000.00
|
| Interest Expense |
$0.00
|
$0.00
|
$14.19 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.03 M
|
$1.39 M
|
$1.12 M
|
$4.18 M
|
$2.63 M
|
$2.28 M
|
$1.10 M
|
$500,000.00
|
$281,000.00
|
$115,000.00
|
| EBITDA |
-$409.49 M |
-$545.07 M |
-$545.87 M |
-$456.73 M |
$626.60 M |
-$705.84 M |
-$392.10 M |
-$269.62 M |
-$160.16 M |
-$94.65 M |
| EBITDA Ratio |
-9.93
|
-6.3
|
-71.17
|
-73.07
|
0.58
|
-103.1
|
-4.36
|
0
|
0
|
0
|
| Operating Income Ratio |
-10.48
|
-6.71
|
-71.17
|
-73.07
|
0.54
|
-103.1
|
-4.36
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$31.70 M
|
$38.36 M
|
$14.21 M
|
$3.02 M
|
$9.85 M
|
$27.89 M
|
$20.36 M
|
$3.04 M
|
$1.18 M
|
$155,000.00
|
| Income Before Tax |
-$400.67 M
|
-$541.49 M
|
-$532.78 M
|
-$457.89 M
|
$606.07 M
|
-$680.24 M
|
-$372.88 M
|
-$270.12 M
|
-$158.99 M
|
-$94.50 M
|
| Income Before Tax Ratio |
-9.71
|
-6.26
|
-69.32
|
-72.59
|
0.54
|
-99.04
|
-4.13
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$29.52 M
|
-$7.07 M
|
$15.52 M
|
-$30.09 M
|
$20.36 M
|
-$3.63 M
|
-$1.49 M
|
-$293,000.00
|
| Net Income |
-$400.67 M
|
-$541.49 M
|
-$503.27 M
|
-$450.83 M
|
$606.07 M
|
-$650.15 M
|
-$372.88 M
|
-$270.12 M
|
-$158.99 M
|
-$94.50 M
|
| Net Income Ratio |
-9.71
|
-6.26
|
-65.48
|
-71.47
|
0.54
|
-94.66
|
-4.13
|
0
|
0
|
0
|
| EPS |
-6.59 |
-9.05 |
-8.49 |
-7.68 |
11.66 |
-12.79 |
-8.08 |
-7.09 |
-4.75 |
-3.4 |
| EPS Diluted |
-6.59 |
-9.05 |
-8.49 |
-7.68 |
11.43 |
-12.79 |
-8.08 |
-7.09 |
-4.75 |
-3.4 |
| Weighted Average Shares Out |
$60.77 M
|
$59.84 M
|
$59.31 M
|
$58.67 M
|
$51.98 M
|
$50.83 M
|
$46.12 M
|
$38.10 M
|
$33.47 M
|
$27.78 M
|
| Weighted Average Shares Out Diluted |
$60.77 M
|
$59.84 M
|
$59.31 M
|
$58.67 M
|
$53.00 M
|
$50.83 M
|
$46.12 M
|
$38.11 M
|
$33.49 M
|
$27.78 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
